Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group,has announced that Roche has exercised its option to increase the scope and value of the cornerstone contract announced on 28 May 2020.
Since the announcement, Oncimmune has been executing the project to profile patient samples collected by Roche during their cancer immunotherapy trials, and following continued discussions, it has been agreed to substantially increase the number of patient samples to be profiled. As a consequence, the overall value of the contract has increased substantially.
The expanded project will continue to explore the baseline and on-treatment autoantibody profiles as biomarkers in patients that received cancer immunotherapy, using Oncimmune’s proprietary SeroTag® biomarker discovery platform.
The overall timeline for the project has not altered with initial results to be provided to Roche within three months and completion in November 2020.
Dr Adam M Hill, CEO of Oncimmune said: “Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling. Importantly, we are delighted to see the substantial value that Oncimmune can contribute to major pharmaceutical and biotechnology companies. With the number of partners utilising our ImmunoINSIGHTS service continuing to grow, I look forward to announcing future projects in the coming few months.”
